Greater preexisting interferon γ responses to mycobacterial antigens and lower bacillary load during hiv-associated tuberculosis

Journal of Infectious Diseases

Volumn 208, Issue 10, 2013, Pages 1629-1633

  Lahey, Timothy ^a,b   Czechura, Tom ^c   Crabtree, Scott ^b   Arbeit, Robert D ^d   Matee, Mecky ^f   Horsburgh, C Robert ^e   Mackenzie, Todd ^a,b   Bakari, Muhammad ^e   Pallangyo, Kisali ^f   Von Reyn, C Fordham ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^f MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

Author keywords

Antigen; HIV; Interferon gamma; Tuberculosis; Vaccine

Indexed keywords

AGAR; BCG VACCINE; CD4 ANTIGEN; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; ISONIAZID; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM VACCINE; PLACEBO; TUBERCULIN;

ADULT; ARTICLE; BACTERIAL LOAD; BACTERIUM CULTURE; CD4 LYMPHOCYTE COUNT; CELL LYSATE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPUTUM SMEAR; TUBERCULIN TEST; TUBERCULOSIS; VIRUS LOAD;

ANTIGEN; HIV; INTERFERON GAMMA; TUBERCULOSIS; VACCINE;

ADULT; ANTIGENS, BACTERIAL; BACTERIAL LOAD; BCG VACCINE; FEMALE; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; TANZANIA; TUBERCULOSIS; VIRAL LOAD; YOUNG ADULT;

EID: 84888633733     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit396     Document Type: Article

References (13)

1. Jouanguy E, Altare F, Lamhamedi S, et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 1996; 335:1956-61.
2. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999; 340:367-73.
3. Lahey T, Sheth S, Matee M, et al. Interferon gamma responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis. J Infect Dis 2010; 202:1265-72.
4. Lahey T, Mitchell BK, Arbeit RD, et al. Polyantigenic interferongamma responses are associated with protection from TB among HIVinfected adults with childhood BCG immunization. PLoS ONE 2011; 6:e22074.
5. von Reyn CF, Mtei L, Arbeit RD, et al. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. Aids 2010; 24:675-85.
6. Munseri PJ, Talbot EA, Mtei L, von Reyn CF. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis 2008; 12:1037-41.
7. Ramsay S. No closure in sight for the 10/90 health-research gap. Lancet 2001; 358:1348.
8. Lahey T, Arbeit RD, Bakari M, et al. Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: A phase III study in Tanzania. Vaccine 2010; 28:7652-8.
9. Jones-Lopez EC, Namugga O, Mumbowa F, et al. Cough aerosols of Mycobacterium tuberculosis predict new infection: A household contact study. Am J Respir Crit Care Med 2013; 187:1007-15.
10. Oni T, Patel J, Gideon HP, et al. Enhanced diagnosis of HIV-1-associated tuberculosis by relating T-SPOT.TB and CD4 counts. Eur Respir J 2010; 36:594-600.
11. Theron G, Peter J, Lenders L, et al. Correlation of Mycobacterium tuberculosis specific and non-specific quantitative Th1 T-cell responses with bacillary load in a high burden setting. PloS ONE 2012; 7:e37436.
12. Lalvani A. Counting antigen-specific T cells: A new approach for monitoring response to tuberculosis treatment? Clin Infect Dis 2004; 38:757-9.
13. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 2004; 38:754-6.